May 9, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 25.34% Profit Margin: A Victory for QuantWave ~1 min.REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecasted by QuantWave, resulting in a profit margin of 25.34%....
May 9, 2025QuantWave Forecast Achieves 24.9% Profit Target for Regeneron Pharmaceuticals, Inc. Stock ~1 min.Regeneron Pharmaceuticals, Inc. stock recently saw the successful achievement of a price target forecast as predicted by QuantWave's automated forecasting platform....
May 9, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Forecast Price Target with a Profit of 24.47% ~1 min.On February 28, 2025, QuantWave's forecasting system signaled a short position for REGENERON PHARMACEUTICALS, INC. stock when the price was at 697.71 $....
April 12, 2025Regeneron Pharmaceuticals Receives Dupixent Approval in Japan ~1 min.Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has recently received approval for its drug Dupixent in Japan....
April 10, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 17.79% Profit: QuantWave's Success ~1 min.REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave, resulting in a profit of 17.79%....
January 2, 2025Regeneron Pharmaceuticals Continues to Impress Investors with Strong Returns ~1 min.In the past five years, Regeneron Pharmaceuticals (NASDAQ:REGN) has delivered a solid return of 89%, making it a favorable choice for investors....
August 13, 2024REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 14.62% ~1 min.REGENERON PHARMACEUTICALS, INC. has successfully achieved the price target forecast as predicted by QuantWave's automated forecasting platform....
February 26, 2025Regeneron Pharmaceuticals Faces Legal Pressure and Growth Potential, According to Analysts ~2 min.Regeneron Pharmaceuticals, Inc. (REGN) is currently facing mounting pressure on both its sales and legal fronts....
January 5, 2025Regeneron Pharmaceuticals: A Strong Performer with Promising Financials ~2 min.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been a steady performer in the biopharmaceutical industry, delivering a decent return of 89% for investors over the last five years....
January 29, 2025Regeneron Pharmaceuticals Inc. REGN: A Leader in Biopharmaceutical Innovation ~2 min.Regeneron Pharmaceuticals Inc. (REGN) is a biopharmaceutical company known for its pioneering work in developing innovative therapies....
